FRI0503 VALIDATION OF NEW POTENTIAL TARGETS FOR REMISSION IN PSORIATIC ARTHRITIS IN PATIENTS TREATED WITH GOLIMUMAB
Those patients had a significant reduction in the number of TJC, SJC, enthesitis and dactylitis (p<0.043). cDAPSA remission was achieved in 5.2%, 33.1% and 38.3% of patients at baseline, 6 mts and 12 mts, respectively. Those patients had a significant reduction in the number of TJC, SJC and enthesitis only (p<0.002). VLDA was achieved in 2.1%, 17.2% and 15.6% of patients at baseline, 6 mts and 12 mts, respectively and those patients had a significant reduction in the number of TJC, SJC, enthesitis and PASI (p<0.002). The overall correlation for DAPSA or cDAPSA remission vs. VLDA achievement were both at 0.999 (Asymptotic Standard Error <0.027) although this is likely driven by the high number of patients who are not in either state. 75% and 53.3% of patients in DAPSA and cDAPSA remission, respectively, also achieved VLDA (p<0.001). In contrast, patients who did not achieve neither cDAPSA nor DAPSA never achieved VLDA. Nonetheless, patients in remission had significantly greater HAQ scores (p<0.03) if they had remaining dactylitis or active skin disease (BSA≤10%; cDAPSA only).
